Asahi Kasei Medical Acquires Bionique

Published on: 
In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter, January 2022, Volume 17, Issue 1

Bionique Testing Laboratories has been acquired by Asahi Kasei Medical and will join the company’s biosafety testing services unit.

Bionique Testing Laboratories, a provider of mycoplasma testing services, has been 100% acquired by a subsidiary of the Japan-based healthcare company, Asahi Kasei Medical. With the acquisition, Bionique will be joined with ViruSure, an Austria-based viral and prion safety testing services company, which is a part of the global biosafety testing services unit of Asahi Kasei Medical’s Bioprocess Division. Both Bionique and ViruSure will continue operations under their existing brands, which Bionique announced in a Dec. 15, 2021 press release.

The acquisition combines Bionique’s mycoplasma and viral safety capabilities with ViruSure’s expertise, expanding Asahi Kasei Medical’s biosafety testing services. Asahi Kasei Medical is also actively investing in facility and employment expansion at various operating sites of both Bionique and ViruSure, according to the press release.

“Joining the Asahi Kasei group will enable Bionique to consolidate its leadership position in the global mycoplasma testing arena and afford our clients access to ViruSure’s service portfolio, satisfying their end-to-end biosafety testing needs from discovery through commercialization,” said Gladis Zamparo, CEO of Bionique, in the press release.

“We are excited to have a strategic partner like Bionique as part of the Asahi Kasei group, and


the expertise in mycoplasma testing that they bring will further strengthen our goal to better

service our customers in all areas of biosafety testing,” said Andy Bailey, CEO of ViruSure, in the press release.

Source: Bionique Testing Laboratories